Portal de Periódicos da CAPES

Recombinant biologic products versus nutraceuticals from plants – a regulatory choice?

2016; Wiley; Volume: 83; Issue: 1 Linguagem: Inglês

10.1111/bcp.13041

1365-2125

Pascal M. W. Drake, Tim H. Szeto, Matthew J. Paul, Audrey Y‐H. Teh, Julian K‐C.,

CRISPR and Genetic Engineering

Biotechnology has transformed the potential for plants to be a manufacturing source of pharmaceutical compounds. Now, with transgenic and transient expression techniques, virtually any biologic, including vaccines and therapeutics, could be manufactured in plants. However, uncertainty over the regulatory path for such new pharmaceuticals has been a deterrent. Consideration has been given to using alternative regulatory paths, including those for nutraceuticals or cosmetic agents. This review will consider these possibilities, and discuss the difficulties in establishing regulatory guidelines for new pharmaceutical manufacturing technologies.